HLA-C and neoplasm: Alterations in genes corresponding to major histocompatibility complex class I (eg, HLA-B or HLA-C) have been postulated to promote tumor evasion of immune surveillance (eg, by restricting neoantigen presentation),9,10 although no guideline recommendations to test HLA genes exist currently.